Dr. Rosen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-218-9150Fax+1 626-218-9149- Is this information wrong?
Summary
- I joined City of Hope as provost and chief scientific officer in 2014. I am responsible for setting the scientific direction of City of Hope, shaping the research and educational vision for the biomedical research, treatment and education institution. I work closely and collaboratively with City of Hope's scientists, clinicians and administrative leaders, to develop strategies that contribute to the organization's mission.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1976 - 1979
- Northwestern University The Feinberg School of MedicineClass of 1976
Certifications & Licensure
- CA State Medical License 2014 - 2026
- IL State Medical License 1977 - 2017
- MD State Medical License 1980 - 1985
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Americas Top Doctors for Cancer Castle Connolly Guide, 2015
- America's Top Doctors Castle Connolly, 2002-2014
- Chicago Magazine: Top Doctors Castle Connolly, 2004, 2006, 2008, 2010, 2012, 2014
- Join now to see all
Clinical Trials
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Start of enrollment: 2015 Jun 11
Publications & Presentations
PubMed
- 536 citationsThe International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.Elias Campo, Elaine S Jaffe, James R Cook, Leticia Quintanilla-Martinez, Steven H Swerdlow
Blood. 2022-09-15 - 376 citationsCloning of a lymphocyte homing receptor reveals a lectin domainLaurence A. Lasky, Mark S. Singer, Ted Yednock, Donald Dowbenko, Christopher Fennie
Cell. 1989-03-24 - 149 citationsPhosphomannosyl receptors may participate in the adhesive interaction between lymphocytes and high endothelial venules.L M Stoolman, T S Tenforde, Steven D. Rosen
The Journal of Cell Biology. 1984-10-01
Journal Articles
- Chronic Lymphocytic Leukemia A Clinical Review, Clinical Review & EducationNabhan Chadi, Rosen ST, JAMA, 1/3/2014
- Update on the Risk Prediction and Prevention of Anticancer therapy-induced CardiotoxicityBhave M, Shah A, Akhter N, Rosen ST, Current Opinions in Oncology, 1/1/2014
- Cardiovascular Toxicity of Biologic Agents for Cancer TherapyBhave M, Akhter N, Rosen ST, Oncology, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...Steven Rosen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid LeukemiaSteven Rosen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...Steven Rosen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Cancer Informatics for Cancer CentersSan Francisco Bay Area - 1/20/2014
- Modern Biologic Therapeutics for CancerSan Francisco Bay Area - 1/20/2014
- Overview of Modern Oncologic TherapiesLas Vegas, NV - 1/6/2014
- Join now to see all
Other
- Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sezary Syndrome: a Consensus Statement of the International Society for Cutaneous Lymphomas (ISCL), t...Olsen EA, Whittaker S, Kim Y, Duvic M, Prince M, Lessin S, Wood G, Willemze R, Demierre M, Pimpinelli N, Bernengo M, Romero P, Bagot M, Estrach T, guitar J, Knobler R,...
1/1/2010 - Clinical Vignettes in Cutaneous T-Cell Lymphoma: Practical Applications for Emerging Data on Mycosis Fungoides/Sezary Syndrome.Rosen ST, Grand Rounds in Hematology, Volume 2 Issue 1
1/1/2009 - Optimizing Management Strategies for Patients with Hematologic Malignancies: A Case-Based Approach.Karp JE, Rosen ST, Pratz KW, Friedberg JW, Franfurt O, Blamble DA, Moran M, McMahon Group
1/1/2008 - Join now to see all
Press Mentions
- City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023
- City of Hope Doctors Present Novel Treatments for Bladder, Blood and Other Cancers at American Society of Clinical Oncology Annual ConferenceMay 27th, 2022
- City of Hope Physicians and Scientists Present New Immunotherapy Research at ASCO Virtual ConferenceJune 3rd, 2021
- Join now to see all
Grant Support
- Transgenic And Targeted MutagenesisNational Cancer Institute2011
- The Robert H. Lurie Comprehensive Cancer CenterNational Cancer Institute2011
- Senior LeadershipNational Cancer Institute2011
- Protocol-Specific Research SupportNational Cancer Institute2011
- Protocol Review And Monitoring SystemNational Cancer Institute2011
- Program LeadersNational Cancer Institute2011
- Planning And EvaluationNational Cancer Institute2011
- Nanomaterials For Cancer Diagnostics And TherapeuticsNational Cancer Institute2011
- Keck BiophysicsNational Cancer Institute2011
- GenomicsNational Cancer Institute2011
- Developmental FundsNational Cancer Institute2011
- Data And Safety Monitoring/Nih PolicyNational Cancer Institute2011
- Clinical Oncology Research Training ProgramNational Cancer Institute2011
- Chicago Cancer Navigation ProjectNational Cancer Institute2011
- Nanomaterials For Cancer Diagnostics And TherapeuticsNational Cancer Institute2010
- Chicago Cancer Navigation ProjectNational Cancer Institute2009–2010
- Transgenic And Targeted MutagenesisNational Cancer Institute2007–2010
- The Robert H. Lurie Comprehensive Cancer CenterNational Cancer Institute2007–2010
- Senior LeadershipNational Cancer Institute2007–2010
- Protocol-Specific Research SupportNational Cancer Institute2007–2010
- Protocol Review And Monitoring SystemNational Cancer Institute2007–2010
- Program LeadersNational Cancer Institute2007–2010
- Planning And EvaluationNational Cancer Institute2007–2010
- Keck BiophysicsNational Cancer Institute2007–2010
- GenomicsNational Cancer Institute2007–2010
- Developmental FundsNational Cancer Institute2007–2010
- Data And Safety Monitoring/Nih PolicyNational Cancer Institute2007–2010
- Clinical Oncology Research Training ProgramNational Cancer Institute1999–2010
- Adenosine Analogs: Therapeutics For Hematologic CancersNational Cancer Institute2005–2009
- AdministrationNational Cancer Institute2007
- The Robert H.Lurie Comprehensive Cancer CenterNational Cancer Institute2001–2007
- Prognostic Impact Of Glucocorticoid Receptors In MyelomaNational Cancer Institute2005–2006
- A Phase I Trial Of Campath-1h And Rituximab In CLL Or Relapsed/Refractory NHLNational Center For Research Resources2004
- 8cl Adenosine Mediated Cytotoxicity In Multiple MyelomaNational Cancer Institute2000–2003
- Robert H Lurie Cancer CenterNational Cancer Institute1993–2000
- Glucocorticoid Receptor Isoforms In Multiple MyelomaNational Cancer Institute1995–1997
- Core--Planning And EvaluationNational Cancer Institute1993–1995
- Core--Developmental FundsNational Cancer Institute1993–1995
- DAB486 IL2 Used In Patients With Selected IL2R Expressing MalignanciesNational Center For Research Resources1991
- IV Cyt-103-90y In Refractory B72.3 Reactive CarcinomaNational Center For Research Resources1990–1991
- Phase II Trial Of Interleukin-2 Treatment Of Cutaneous T-Cell LymphomasNational Center For Research Resources1990
- MCA 1311-Lym-1 Patients With Diffuse, Aggressive LymphomaNational Center For Research Resources1990
- Treatment Of Ovarian Cancer With Monoclonal AntibodiesNational Center For Research Resources1988–1989
- Treatment Of Lymphocytic Leukemia With Monoclonal AntibodiesNational Center For Research Resources1988–1989
- Treatment Of Lung Cancer With Monoclonal AntibodiesNational Center For Research Resources1988–1989
- Radiolabeled Monoclonal Antibody T101 Treatment Of Cutaneous T-Cell Lymphoma (HumNational Center For Research Resources1987–1989
Professional Memberships
- Member
Hospital Affiliations
- City of Hope Comprehensive Cancer CenterDuarte, California
- City of Hope Comprehensive Cancer CenterDuarte, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: